Japan approvals for Kadcyla, Ultibro and Flutiform
This article was originally published in Scrip
Executive Summary
Among the new products receiving formal final approval in Japan are Chugai/Roche's Kadcyla for breast cancer, Novartis's Ultibro for chronic obstructive pulmonary disease (COPD) and Kyorin's Flutiform for adult bronchial asthma.